New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease.
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease. Nature cancer Lemaitre, L., Adeniji, N., Suresh, A., Reguram, R., Zhang, J., Park, J., Reddy, A., Trevino, A. E., Mayer, A. T., Deutzmann, A., Hansen, A. S., Tong, L., Arjunan, V., Kambham, N., Visser, B. C., Dua, M. M., Bonham, C. A., Kothary, N., D'Angio, H. B., Preska, R., Rosen, Y., Zou, J., Charu, V., Felsher, D. W., Dhanasekaran, R. 2024Abstract
Hepatocellular carcinoma (HCC) frequently recurs from minimal residual disease (MRD), which persists after therapy. Here, we identified mechanisms of persistence of residual tumor cells using post-chemoembolization human HCC (n?=?108 patients, 1.07 million cells) and a transgenic mouse model of MRD. Through single-cell high-plex cytometric imaging, we identified a spatial neighborhood within which PD-L1?+?M2-like macrophages interact with stem-like tumor cells, correlating with CD8+ T cell exhaustion and poor survival. Further, through spatial transcriptomics of residual HCC, we showed that macrophage-derived TGFß1 mediates the persistence of stem-like tumor cells. Last, we demonstrate that combined blockade of Pdl1 and Tgfß excluded immunosuppressive macrophages, recruited activated CD8+ T cells and eliminated residual stem-like tumor cells in two mouse models: a transgenic model of MRD and a syngeneic orthotopic model of doxorubicin-resistant HCC. Thus, our spatial analyses reveal that PD-L1+ macrophages sustain MRD by activating the TGFß pathway in stem-like cancer cells and targeting this interaction may prevent HCC recurrence from MRD.
View details for DOI 10.1038/s43018-024-00828-8
View details for PubMedID 39304772
View details for PubMedCentralID 8959995